Clinical trial · Observational
Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
Brain Integrity in Survivors of Hodgkin Lymphoma (HL) Treated With Thoracic Radiation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
While thoracic radiation therapy (TRT) has been a primary component in successful treatment of a variety of childhood and adult cancers, the exposure to this treatment has been associated with significant cardiovascular and pulmonary morbidity in long-term survivors. Within non-cancer populations, cardiovascular and pulmonary morbidity is associated with increased risk for cerebral vascular accidents (CVAs), accelerated brain atrophy and neurocognitive impairment. Patients with chronic heart disease demonstrate problems with attention, processing speed, memory, and executive functions. Chronic pulmonary disease also increases the risk of stroke, leukoencephalopathy, and neurocognitive impairment in non-cancer populations. The investigators propose to examine indices of brain integrity, including neurocognitive performance and brain MRI/MRA, in long-term adult survivors of Hodgkin lymphoma (HL) treated with thoracic radiation and no direct central nervous system therapy. OBJECTIVES: 1. To evaluate brain integrity in adult survivors of childhood HL treated with thoracic radiation therapy. 2. To identify therapeutic factors associated with brain integrity in adult survivors of childhood HL who are at risk for cardiac and pulmonary morbidity. 3. To examine associations between cardiac, vascular and pulmonary health and brain integrity in adult survivors of childhood HL treated with thoracic radiation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (10)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cardiopulmonary Exercise Testing | Other | — | UNRESOLVED |
| Echocardiography | Other | — | UNRESOLVED |
| Health Questionnaire | Other | — | UNRESOLVED |
| Neurocognitive Evaluation | Other | — | UNRESOLVED |
| Neurologic Evaluation | Other | — | UNRESOLVED |
| Ophthalmology Examination | Other | — | UNRESOLVED |
| Pulmonary Function Testing | Other | — | UNRESOLVED |
| Quantitative Brain Imaging | Other | — | UNRESOLVED |
| Serum Biomarkers |
Design
Arms and outcomes
Arms (2)
- label
- Hodgkin lymphoma
- description
- Participants previously treated at St. Jude Children's Research Hospital with thoracic radiation therapy for Hodgkin lymphoma. Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination.
- interventionNames
- Other: Neurocognitive Evaluation
- Other: Quantitative Brain Imaging
- Other: Neurologic Evaluation
- Other: Health Questionnaire
- Other: Vascular Testing
- Other: Cardiopulmonary Exercise Testing
- Other: Echocardiography
- Other: Pulmonary Function Testing
- Procedure: Serum Biomarkers
- Other: Ophthalmology Examination
- label
- Normal control
- description
- A group of healthy individuals matched for age, sex and race. Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria - HL participant: * Current St. Jude LIFE protocol Participant, treated with thoracic radiation * Currently ≥ 18 years of age * ≥ 10 years from original diagnosis Exclusion Criteria - HL participant: * Has participated in the previous pilot study at St. Jude (HPP16) * History of cranial or total-body radiation therapy * History of intrathecal Methotrexate, high-dose Methotrexate or high-dose Cytarabine. * History of head injury or diagnosis of a genetic disorder associated with neurocognitive impairment * Pre-existing known neurocognitive impairment prior to diagnosis of Hodgkin lymphoma * History of congenital heart disease reported in the literature to be associated with neurocognitive status as determined by the principal investigators * Currently pregnant * Secondary central nervous system neoplasm Inclusion Criteria - Normal Control: * Research participant is a sibling, parent, relative or friend of a current or former St. Jude patient * Research participant must be at least 18 years of age at the time of the scheduled evaluation Exclusion Criteria - Normal Control: * History of cranial, total-body or thoracic radiation therapy * History of intrathecal Methotrexate, high-dose Methotrexate, or high-dose Cytarabine. * History of head injury or diagnosis of a genetic disorder associated with neurocognitive impairment * Known neurocognitive impairment * History of congenital heart disease reported in the literature to be associated with neurocognitive status as determined by the principal investigators * Currently pregnant * Central nervous system neoplasm
References
Publications (1)
- DERIVEDKhan RB, Hanzlik E, Deokumar S, Xie L, Hudson MM, Krull KR, Sabin ND. Neurologic Morbidity in Survivors of Childhood Hodgkin Lymphoma Treated With Radiation. Pediatr Blood Cancer. 2026 Aug;73(8):e70398. doi: 10.1002/1545-5017.70398. Epub 2026 May 12. PMID 42116823